

- Carpal tunnel syndrome, 1084
in diabetes, 815
in rheumatoid arthritis, 772
- Carpopedal spasm, 732
- Carvedilol
for heart failure, 63
for hypertensive patients with diabetes, 176
- Castrate-resistant prostate cancer (CRPC), 607
- Casts, in urine, 296f
- Cat-scratch disease, 844
- Catamenial epilepsy, 1051-1052
- Catamenial pneumothorax, 250
- Cataplexy, narcolepsy with, 972
- Cataracts, 1002
in diabetic patients, 670
- Catastrophic antiphospholipid syndrome, 785
- Catatonic stupor, 969
- Catecholaminergic polymorphic ventricular tachycardia, 133
- Catheter, vascular, infections associated with, 915
- Catheter ablation
for arrhythmias, 115-116
for atrial fibrillation, 128-129, 128f
for atrioventricular nodal reentry tachycardia, 121
of atrioventricular node, 129
in Wolff-Parkinson-White syndrome, 123
- Catheter-associated urinary tract infections, 912-914, 914f, 914.e1t
- Cauda equina syndrome, 1001
- Cavernous sinus thrombosis, septic, 864-865
- CD4 T cells, 827, 829
in HIV infection, 938
opportunistic infections and, 931
progressive, 931t
monitoring interval for, 932
- CD8⁺ T cells, 828
- Ceftriaxone
for cholecystitis, 896
for Lyme meningitis, 858-859
- Celiac disease, 383
- Celiac sprue, 383
- Cell-mediated immunity defects
agents causing infection in, 943-944
conditions causing, 944t
- Cell-mediated response, 829
- Cells, in urine, 293f
- Cellular redistribution, hyperkalemia and, 305
- Cellulitis, 884, 885f
- Centimorgan (cM), 8
- Central cyanosis, 26
- Central diabetes insipidus, 632, 632t
- Central line-associated bloodstream infection (CLABSI), 914f, 915, 914.e1t
- Central nervous system (CNS)
focal lesions of, in HIV-infected patients, 939-940
symptom localization in, 961t
without focal lesions of, in HIV-infected patients, 940
- Central nervous system (CNS) tumors, 1064-1068. *see also* Brain tumors.
clinical presentation of, 1064-1065
definition of, 1064
diagnosis/differential, 1065-1066, 1065f-1066f
epidemiology of, 1064
- Central nervous system (CNS) tumors
(Continued)
pathology of, 1064
prognosis of, 1067
treatment of, 1066-1067
- Central sleep apnea, 971
- Central sympatholytics, 173t
contraindications and side effects of, 174t
- Central venous catheter-related bloodstream infections, 883
- Central venous pressure, 59
- Cerebellar ataxias, 1021-1022, 1022t
- Cerebellum, 1013, 1015f
disorders of, 1013-1015
- Cerebral aneurysms, in autosomal dominant polycystic kidney disease, 334
- Cerebral edema
after traumatic brain injury, 1047
hyponatremia correction and, 302
liver failure and, 457
magnetic resonance imaging of, 862f
- Cerebral infarction, 1039
- Cerebral perfusion pressure (CPP), 1037
in traumatic brain injury, 1047
- Cerebral salt wasting, 300-301
- Cerebral venous sinus thrombosis, 1006
- Cerebritis, 862
- Cerebrospinal fluid (CSF)
Creutzfeldt-Jakob disease and, 866
in demyelinating neuropathy, 1083
diagnosis of infection in, with India ink examination, 857
in encephalitis, 859
hypocretin level in, in narcolepsy, 972
IgG in, multiple sclerosis, 1070
in infectious endocarditis, 865
investigation of, 963
in meningitis
bacterial, 855
fungal, 857
spirochetal, 857
tuberculous, 857
in multiple sclerosis, 1070, 1071f
seizures and, 1058
- Cerebrovascular disease, 1033-1045. *see also* Stroke.
clinical presentation of, 1038-1039
common forms of, 1033t
definition of, 1033-1034
diagnosis and differential diagnosis of, 1039-1041
epidemiology of, 1033-1034
modifiable risk factors of, 1034, 1034t
Parkinsonism and, 1019
pathology of, 1034-1038
prognosis of, 1044-1045
vascular anatomy of, 1035-1036, 1035f
vascular pathogenesis of, 1036-1037
- Certolizumab, for rheumatoid arthritis, 774t
- Certolizumab pegol, for Crohn's disease, 423
- Ceruloplasmin, in Wilson's disease, 1020
- Cervical cancer
in HIV-infected patients, 933
human papillomaviruses and, 581-582
screening for, 583
of women, 701, 702t-703t
- Cervical radiculopathy, 1000
- Cervical spinal myelopathy, cervical spondylitis and, 1000
- Cervical spine, subluxation of, in rheumatoid arthritis, 772
- Cervical spondylosis, 1000-1001, 1001t
- Cervicitis, 918-921
- Cetuximab, 589-590, 590t
- CFTR chloride channel, proposed structure of, 217.e1f
- CHADS₂ score, 125
- Chagas' disease, 955, 955.e2f
- Chancroid, 844, 925
- Channelopathies
epilepsy in, 1052
genetic testing for, 133
muscle, cardiomyopathies associated with, 1094-1095
- Charcot joints, 815-816
- Charcot-Marie-Tooth disease, 1085-1086, 1085.e1t
- Charcot's triad, 474
- Chédiak-Higashi syndrome, 556
- Cheiroarthropathy, diabetic, 815
- Chemicals, cancer risk and, 582-583
- Chemokine receptor CCR5, 928-930
- Chemokines, 823
- Chemopreventive agents, cancer and, 583
- Chemoradiation therapy, for pancreatic carcinoma, 437
- Chemotaxis, of neutrophils, 515
- Chemotherapy, 587t
for brain tumors, 1066
definition of, 586
indications for, 587-588, 587t
limitations of, 588
for lung cancer, 269-270
in non-small cell lung cancer, 597
side effects of, drugs for, 591
for small cell lung carcinoma, 270
in testicular cancer, 608
- Chest, physical examination of, 187-188
- Chest pain, 23-24
aortic dissection and, 344
cardiovascular causes of, 23t
in esophageal disease, 397
ischemic, hypertrophic cardiomyopathy and, 142
lung cancer and, 266
noncardiac causes of, 24t
recurrent, myocardial infarction and, 106
in respiratory disorder, 186
- Chest radiography
in acute respiratory distress syndrome, 262, 262.e1f
for atrial septal defects, 68
for atrioventricular septal defects, 70
in cardiovascular disease, 37-39, 37f
in chronic obstructive pulmonary disease, 212, 212.e1f
in heart failure, 59, 60f
in interstitial lung disease, 236
of lung diseases, 203
of lung structure, 203, 203.e1f
in pericardial effusions, 137
of pleural effusion, 203, 248, 248.e1f
for *Pneumocystis pneumonia*, 257, 257.e1f
in pneumonia, 254, 875, 254.e1f